

WADA Technical Letter – TL05

Document Number:	TL05 (replaces TL02/2015)	Version Number:	2.0
Written by:	WADA LabEG	Approved by:	WADA LabEG*
Date:	07 May 2015	Effective Date:	07 May 2015

*The approval by the WADA Executive Committee is applicable only to Technical Letters issued after November 2019.

ANALYSIS OF OXILOFRINE

The *World Anti-Doping Agency* wishes to draw the attention of the Laboratories to the following remarks and instructions on the analysis and reporting of **oxilofrine** (methysynephrine) intake.

Hydroxy-pseudoephedrine ('pseudo-oxilofrine') is a minor *Metabolite* of pseudoephedrine, which under certain conditions may co-elute with oxilofrine and show an identical fragmentation pattern in LC-MS analyses. This may lead to the incorrect reporting of an *Adverse Analytical Finding* for oxilofrine, a Non-Threshold Substance. Therefore, it is requested that Laboratories implement procedures that allow the proper chromatographic separation and identification of these two compounds, for example by performing GC-MS analysis of the per-trimethylsilyl (TMS) derivatives, prior to reporting an oxilofrine case. Oxilofrine and hydroxy-pseudoephedrine can also be separated by UHPLC.

Should you have any further questions, please do not hesitate to contact the *WADA* Science Department.